ArticleDiscover oncology2025
A bibliometric analysis of atezolizumab in hepatocellular carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is a highly prevalent primary liver cancer, accounting for over 90% of all liver cancer cases worldwide and ranking as the third leading cause of cancer-related deaths. The emergence of molecular targeted therapies has completely transformed the treatment landscape for HCC. Among them, sorafenib, as the first molecular targeted drug approved by the FDA, established a treatment standard that lasted for over a decade. However, recent research breakthroughs have shown that the combination therapy of atezolizumab and bevacizumab demonstrates superior efficacy compared to sorafenib, and this combination was approved by the FDA in 2020. Numerous studies have been published on the treatment of hepatocellular carcinoma with atezolizumab; however, no bibliometric study has been published. The aim of this study is to better understand the current situation and identify potential new research directions by conducting a bibliometric analysis on the treatment of hepatocellular carcinoma with atezolizumab.
methodsWe searched the Web of Science Core Collection (WoSCC) for articles related to the treatment with Atezolizumab for HCC. Two software (VOSviewer and CiteSpace) were primarily used to assess the contribution and co-occurrence relationships of various countries/regions, institutes, journals, and authors. They were also employed to identify the research hotspots and potential development trends in this research field.
objectiveTo understand the development status and future trends of atezolizumab in the treatment of hepatocellular carcinoma, we used bibliometric analysis to investigate the cooperation and influence among countries, institutions, authors and journals.
resultsA total of 1067 articles published by 6318 authors from 1747 institutions in 254 journals from 2016 to 2024 were retrieved. A rapid increase in articles published after 2020 was observed and peaked in 2023. China has the largest number of publications and citations. ASSISTANCE PUBLIQUE HOPITAUX PARIS (APHP), NATIONAL TAIWAN UNIVERSITY, and UNIVERSITE PARIS CITE(n = 92, 8.62%) are the three leading institutions for research on this topic. KUDO M and FINN RS have had the greatest academic influence in this area. Most of the publications were published in the journal CANCERS, while the most cited journal was j hepatol. The main aspects of atezolizumab in the treatment of hepatocellular carcinoma include immunotherapy, hepatocellular carcinoma, research methods, survival prognosis, and targeted therapy. Hepatocellular carcinoma, sorafenib, atezolizumab, atezolizumab plus bevacizumab, bevacizumab, immunotherapy and other keywords are hot words in this field in recent years.
conclusionAtezolizumab has become an increasingly popular treatment for hepatocellular carcinoma. Future studies should focus on the efficacy of atezolizumab plus bevacizumab and TACE-HAIC combination therapy in patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.